Ruth Howells
Senior Director, Health Technology Assessment
Ruth is Head of Health Technology Assessment (HTA) at Clarivate. Ruth has overall responsibility for our Global HTA services and has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of procedural processes.
Ruth oversees our global HTA services from early scientific advice, through local submissions and global HTA programs to post-submission support. With extensive experience of managing HTA submissions globally, Ruth works closely with our clients and in-house team, advising manufacturers on their role and requirements, and significantly contributes to the development and communication of the HTA strategy and evidence generation planning from an early stage.
Prior to joining Clarivate, Ruth worked for the National Institute for Health and Care Excellence (NICE) and has over 20 years’ experience in health outcomes research. Ruth has an MSc in Health Economics from the University of York and her experience in health outcomes research covers a wide range of therapeutic areas including, oncology (cervical cancer, head and neck cancer, colorectal cancer, breast cancer), respiratory disease, cardiology, nephrology, gynecology, gastroenterology and dermatology. Ruth is an expert in HTA for rare diseases and in innovative therapies such as cell and gene therapies.
Latest news
Clarivate’s IPfolio and Renewal Services Selected by IGT
Managing global intellectual property more efficiently with trusted data, expert support and integrated services London, U.K. May 21, 2026: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today…
Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform
New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility London, U.K. May 19, 2026: Clarivate Plc (NYSE:CLVT), a…
Clarivate Identifies Five Medtech Trends Set to Redefine Growth Opportunities in 2026
New Medtech Trends to Watch report highlights market shifts, care delivery changes and competitive dynamics poised to reshape medtech strategy London, U.K. May 13, 2026. Clarivate Plc (NYSE:CLVT), a leading…
